AstraZeneca PLC closed 20.36% short of its 52-week high of £133.88, which the company achieved on September 3rd.

AstraZeneca PLC (NASDAQ:AZN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. AstraZeneca PLC (NASDAQ:AZN ...

AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory ...

The decline in the company's share price came as its shares traded ex-date following the announcement of a ₹32 per share ...

One, it makes sense for AstraZeneca Plc to move its main listing to New York, and two, such a terrible symbolic blow for the ...

AstraZeneca PLC closed 21.60% below its 52-week high of £133.88, which the company achieved on September 3rd.

AstraZeneca has announced a new clinical study titled ‘Exacerbations and Their Outcomes in Egyptian Patients (EXACOS EG Population),’ which aims to explore the burden of severe exacerbations of COPD ...

Dr Conall Watson, consultant epidemiologist at the UK Health Security Agency, said: "Having an RSV vaccine from week 28 in every pregnancy is key to protecting your baby against RSV bronchiolitis.

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

AstraZeneca PLC on Wednesday announced that its antibody anselamimab did not achieve statistical significance in the overall patient population, thought it noted a "meaningful improvement" in ...

Astrazeneca plc reported results from its BaxHTN phase III trial showing aldosterone synthase inhibitor (ASI) baxdrostat met primary and secondary endpoints in patients with uncontrolled or ...

AstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain depleter antibody, anselamimab, in certain patients with a rare disease called ...